Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756247 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02756247: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02756247 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02756247, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the combination of buparlisib and ibrutinib will lead to better treatment results in patients with relapsed or refractory Follicular lymphoma, (FL) Mantle cell lymphoma (MCL) or Diffuse Large B-cell lymphoma (DLBCL). The investigators are using buparlisib and ibrutinib because both drugs seem to block different proteins that allow cancer cells to keep growing. Blocking these proteins may help by making the cancer cells undergo cell death, which will stop uncontrolled tumor growth.
Interventions
- DRUG Ibrutinib
- DRUG Buparlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2022-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756247
The ClinicalTrials.gov registry entry for NCT02756247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT02756247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756247 about?
NCT02756247 is a clinical study titled "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma". The purpose of this study is to find out if the combination of buparlisib and ibrutinib will lead to better treatment results in patients with relapsed or refractory Follicular lymphoma, (FL) Mantle cell lymphoma (MCL) or Diffuse Large B-cell lymphoma (DLBCL). The investigators are using buparlisib ...
What is the current status of trial NCT02756247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2016-05-09. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT02756247?
The interventions under investigation include: Ibrutinib (DRUG), Buparlisib (DRUG).
Who is sponsoring clinical trial NCT02756247?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.